Literature DB >> 28178330

Comparative study of extrapolative factors linked with oxidative injury and anti-inflammatory status in chronic kidney disease patients experiencing cardiovascular distress.

Mahmood Rasool1, Muhammad Abdul Basit Ashraf2, Arif Malik2, Sulayman Waquar2, Shahida Aziz Khan3, Mahmood Husain Qazi4, Waseem Ahmad1, Muhammad Asif5, Sami Ullah Khan6, Ahmad Zaheer7, Muther Mansoor Qaisrani8, Abdul Rehman Khan9, Aamir Iqbal7, Amir Raza7, Saima Iram10, Kashif Kamran11, Asim Iqbal11, Mohammad Zahid Mustafa12, Hani Choudhry13, Mazin A Zamzami14, Wesam H Abdulaal14, Mohammad Sarwar Jamal3.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is a group of heterogeneous abnormalities affecting the function and structure of the kidney and mostly further proceeds to cardiovascular damage prior to end stage renal disease (ESRD). The oxidative insult and inflammatory mediators have some undefined role in CKD and cardiovascular complications. It is therefore, aimed at to pin point the predictive factors in the development of cardiovascular disorder in patients with chronic kidney disease.
METHODS: Fifty patients of CKD experiencing cardiovascular distress and twenty normal individuals having same age and sex acted as control during these observations. Blood samples (Each 5 ml) were drawn and subjected to centrifugation for 10-15 minutes to separate the serum at 4000-5000rpm. The levels of MDA, GSH, SOD, CAT, VIT C, VIT E, IL-1, TNF-alpha, nitric oxide (NO) and advanced oxidation protein products (AOPPs) were estimated and analyzed.
RESULTS: The nitric oxide levels in the CKD patients decreased significantly (13.26±1.25 ng/ml) compared to controls (42.15±5.26 ng/ml). The serum vitamin E and C levels in these patients recorded 2.15±0.25 μg/ml and 0.97±0.09 μg/ml respectively as against their assigned controls which read 6.35±1.22 μg/ml and 3.29±0.25 μg/ml. Furthermore, a significantly higher level of Malondialdehyde (MDA) as1.25±0.07 nmol/ml was observed in CKD patients viz-a-viz relevant control. However, the serum SOD, catalase (CAT) and GSH levels in the same patients registered a significant decline as evident from respective figures 0.07±0.002 μg/dl, 1.22±0.012 μmol/mol, and 3.25±1.05 μg/dl. The control for these was observed as0.99±0.06 μg/dl, 3.19±0.05 μmol/mol, and 8.64±0.03 μg/dL. On the other hand, the IL-1 levels in the CKD patients found quite higher (402.5±18.26 pg/ml). This clearly points to substantial increase in oxidative insult and reduced NO levels leading to the renal and cardiovascular damage.
CONCLUSION: Observations support the fact that the decrease in anti-oxidative capacity accompanied by higher inflammatory mediators in CKD is indicative of oxidative stress, consequently leading to CKD progression, in all probability to cardiovascular insult. The outcome reiterates that strategies be designed afresh to contain CKD progression to cardiovascular complications and ESRD. One way could be to focus on early detection of stress related to the disease. It requires analyzing the factors related to stress, such as the one reported here. Linking these factors with the symptoms could be a crucial step forward. And further, the disease could be monitored in a more disciplined manner.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28178330      PMCID: PMC5298283          DOI: 10.1371/journal.pone.0171561

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

CKD (Chronic kidney disease) is group of heterogeneous conditions affecting the structure and function of kidney. Acute kidney injury, intake of nephrotoxins, weight gain, smoking and increasing age are the factors linked to it [1]. Structural features attached like, augmentation in glomerulosclerosis, renal vasculopathy, tubular inflammation, fibrosis, atrophy together with presence of scar tissue, have also been thoroughly identified [2]. Earlier pathological variations in kidney may occasionally happen in the absence of clinical presentation due to high adaptability [3]. Notwithstanding, these physiological studies, what is more serious is CKD progression once adaptive threshold is broken, progression to end stage renal disease is impending. Hence, identifying its stage is imperative. For that, determining the loss of glomerular filtration rate (GFR) is the primary clinical manifestation. The CKD acquire more serious proportion as patients are more prone to die of cardiovascular diseases (CVD) than the actual renal failure. The association between CKD and CVD assumes greater proportion since both have same risk factors and the disease related circumstances in one system can adversely affect the other system. Understandly, in the prior CKD stage, the incidence of CVD events becomes higher could possibly due to glomerular filtration rate (GFR), aggravate the severity of CVD abnormalities. This is reinstated by a study, where in CKD patients with stage III and IV, the incidence of CVD is 4–5 times higher than population [4]. Hypertension is a highly implicated etiological factor also for the induction of CVD in CKD patients. It is because; sodium retention and activation of renin angiotensin system (RAS), are the underlying mechanisms get stressed. Also directly, hypertension causes cardiac deterioration in CKD, as the induction of left ventricular hypertrophy takes place. And further consequently results in the decrease of coronary reserves and capillary density, leading to coronary ischemia [5]. In CKD further, uremia results in production of cyanate in the presence of hydrogen peroxide (H2O2) and myeloperoxidase (MPO) mediates carbamylated protein synthesis that combines with high density lipoprotein (HDL). On its part, carbamylated HDL reduces lecithin cholesterol acyl transferase (LCAT) activity, so important in cholesterol esterification and HDL maturation and incidently, leading to CVD events in CKD patients [6]. The CKD persons are linked to the complications in cellular respiration as well–directly or indirectly to the stress. Oxidative stress occurs either due to inability of scavenging free radicals by antioxidative enzymes or excessive reactive oxygen species (ROS) production by electron transport chain (ETC) in mitochondria as a primary source [7]. It is indicated by compromised mitochondrial respiration in CKD patients, resulting in diminished ATP production affecting a reduction in glutathione mediated redox balance because the glutathione formation rate is ATP dependent [8,9]. Hence, the alternate ways to reduce such complications are vital. The antioxidative defense system is one such mechanism, if primary antioxidants; superoxide dismutase, catalase and glutathione peroxidase are impaired [10]. Their decrease directly retard processing of superoxide free radical (O.2¯) as its level is increased; cell membrane is damaged which is determined on its part by malondialdehyde (MDA) levels [11] and protein oxidation assessed by advanced oxidation protein products (AOPPs) [10]. There is another angle to impairement of respiratory process involving enzyme dealing NADPH–another energy carrier molecule. Tumor necrosis factor-alpha (TNF-α), interleukin 1 and 6 induce NADPH oxidase for generation of superoxide free radicals [12]. Thus, there is dual increase in free radicals; one by reduced antioxidative capacity and two by inflammatory mediators. There are reports for the formation of peroxynitrite (ONOO¯) radicals by the reaction of O.2¯ free radicals to nitric oxide (NO) mediated by nitric oxide synthase (NOS) inducing lipid peroxidation further [13]. The NO utilization, results in vasoconstriction causing vascular injury. In CKD, vitamins C and E (α-tocopherol) have a pivotal significance. There are non-enzymatic antioxidants. The synthesis of active form of vitamin C, ascorbate is dependent on reduced glutathione which is reduced in CKD [14]. Vitamin E hampers lipid peroxidation and is restored by vitamin C thus both are inter-dependent [15]. This is a significant example of an antioxidant network susceptible to malfunctioning in CKD patients. Hence, the main aim of this study is to investigate the implications of extrapolative factors useful in these diseases especially in development of cardiovascular disease in such patients also diagnosed with chronic kidney impairements causing renal failure.

Materials and methods

Fifty patients affected with chronic kidney diseases were enrolled in the study at Jinnah Hospital, Lahore. Clinical diagnosis and history of the patients were obtained from hospital medical records. Concurrently, twenty healthy people acted as control. Informed written consent was obtained prior to the start of study as per Helsinki declaration. The Study was approved by the ethical committee of the University of Lahore. Five ml of blood was drawn from each patient and control subjects and centrifuged at 4000 rpm for serum separation and the samples transported immediately to the laboratory for further processing. All the chemical and reagents used in this study were of analytical grades and purchased from Sigma chemicals Co. (St. Louis, Mo, USA).

Inclusion and exclusion criteria

All the patients included were at the stage V of CKD with confirmed clinical reports of glomerular filtration rate (GFR) of less than 15. The CKD patients with the history of hyperextension, cigarette smoking, and alcohol consumption were excluded from the study.

Estimation of Glutathione (GSH)

Glutathione was estimated as per protocol of Moron et al., [16]. The 100μl of serum was taken and added 0.02M (2.4μl) EDTA and ice-cooled (10 min), Followed by addition of 2 ml distilled water. To this 50.0μl of TCA (50%) was added and incubated on ice (10–15 min). Samples were then centrifuged (3500 rpm). The supernatant was removed and added with 2ml of 0.15M Tris. HCl and 0.05ml (DTNB). Absorbance was measured at 412nm.

Estimation of Catalase (CAT)

Catalase (CAT) was determined by the method of Aebi, [17]. 100μl of sample was added in the tube followed by 1.9ml of phosphate buffer and 1ml of H2O2. At last three absorbance were measured after every minute at the wavelength of 240nm.

Determination of Superoxide Dismutase (SOD)

Superoxide dismutase (SOD) was estimated as perKakkar procedure [18]. The 100μl of sample was taken in tube, added with 1.2ml of PBS, 100μl of phenazine methosulfate, 300μl of NBT and 200μl of NADH. Thereafter, 100μl of Glacial acetic acid and 4ml of 2-propanol was added further in tube and centrifuged (3000 rpm, 10 min). The absorbance was taken at 560nm.

Estimation of Malondialdehyde (MDA)

This method used Ohkawa et al Procedure [19]. 200μl of the sample was taken in the tube,to which 200μl of 8.1% SDS and 1.5ml of 20% acetic acid was added. Later 1.5ml of 0.8% TBA and 600μl of distilled water along with 4ml of 2-propanol was supplemented. It was centrifuged (4000 rpm, 10 min) and supernatant was removed for measuring absorbance at 532nm using UV-1100 spectrophotometer.

Advanced Oxidative Protein Products (AOPPS) determination

AOPPs were estimated by the method of Witko-Sarsat et al., [20]. 200μl of sample was first diluted with PBS, then 10μl of KI (1.16M) and 20μl of acetic acid was added. The sample centrifuged (5000 rpm, 5min) and absorbance was taken at 340nm on UV-spectrophotometer.

Estimation of Nitric Oxide (NO)

Bories and Bories method employed for this purpose [21]. 100μl of Griess Reagent was added with 300μl of sample and supplemented with 2.6ml of distilled water followed by incubation (30 min). The absorbance was measured at 548nm.

Estimation of vitamin C

For estimation of Vitamin C method of Chinoy et al., followed [22]. 100μl of the sample was added with 400μl of TCA 5% and centrifuged (3000 rpm, 10 min). 320μl of supernatant was separated and added with 130μl of DTC and allowed to heat (90°, 1hr). It was later ice-cooled and added with 600μl of sulphuric acid then subjected to absorbance at 520nm.

Estimation of vitmain E

Vitamin E was estimated by the method of Rosenberg [23]. 200μl of the sample was supplemented with 200μl of ethanol, 200μl of n-hexane and distilled water. It was then centrifuged (3000 rpm, 10 min) and added with 25μl of Bathophenanlhroline, 75μl of ferric chloride and 50μl of Orthophosphoric Acid. Its absorbance was taken at 536nm.

IL-1 and TNF-alpha determination

Estimation of interleukin-1 and tumor necrosis factor (TNF-alpha) were performed by using ELIZA kits (R&D Systems, MN, USA and Affimatrix) respectively).

Statistical analysis

The Statistical Analysis was performed by SPSS version 17.0. Independent T-test was performed by taking average means of group populations. Pearson's correlation coefficient was used to assess correlations among different variables in CKD patients. The p-values were computed using one way ANOVA.

Results

The data presented in the Fig 1 shows the clear picture of different parameters estimated in the patients suffering from CKD. When oxidative stress biomarkers were estimated, increase in MDA levels was observed in the CKD patients as compared to controls (1.25±0.07 vs 0.07±0.01 nmol/ml). GSH levels in the CKD patients were markedly lower (3.25±1.05μg/dL) as compared to control (8.64±0.03 μg/dL). The serum SOD levels in the CKD patients lowered (0.07±0.002 μg/dL) in comparison to control group (0.99±0.06 μg/dL). The catalase (CAT) levels in CKD patients lowered in comparison to the control group (1.22±0.012 vs 3.19±0.05 μmol/mol of protein). When the levels of vitamins were measured, serum vitamin E levels in the CKD patients were 2.15±0.25 μg/ml while, in healthy individuals were 6.35±1.22 μg/ml. Likewise, the level of vitamin C in CKD patients was significantly (p = 0.021) low (0.97±0.09 μg/ml) as compare to controls (3.29±0.25 μg/ml). The IL-1 levels in the CKD patients were estimated as 402.5±18.26 pg/ml while in the healthy individuals as 219.65±15.26 pg/ml. The TNF-α levels in CKD were 37.26±4.26 pg/ml while in control ones 18.65±2.25 pg/ml. When the AOPPs levels were measured in CKD patients, the value was significantly higher (3.25±0.07 ng/ml) than those measured in controls (1.09±0.02 ng/ml). The nitric oxide levels in the CKD patients were significantly decreased as compared to those in the controls (13.26±1.25 vs 42.15±5.26 ng/ml). The significant findings were that reduction in NO and vitamin C results in increase in IL-1 which mediates excessive ROS generation resulting in cardiovascular insult in CKD patients prior to ESRD (Table 1).
Fig 1

Biochemical profile of CKD patients experiencing CVD linked with oxidative injury and anti-inflammatory status.

Table 1

Result of all the variables among CKD patients and control.

VariablesControl (n = 20)Patients (n = 50)p-value
Vitamin E (μg/ml)6.35±1.222.15±0.250.026*
Vitamin C(μg/ml)3.29±0.250.97±0.090.021*
MDA (nmol/ml)0.07±0.011.25±0.070.046*
GSH (μg/dL)8.64±0.033.25±1.050.033*
SOD (μg/dL)0.99±0.060.07±0.0020.011*
CAT (μmol/mol of protein)3.19±0.051.22±0.0120.035*
IL-1 pg/ml219.65±15.26402.5±18.260.002*
TNF-α (pg/ml)18.65±2.2537.26±4.260.002*
AOPPs1.09±0.023.25±0.070.032*
Nitric Oxide (NO)42.15±5.2613.26±1.250.023*

*Significant (p-value <0.05).

*Significant (p-value <0.05).

Discussion

For the purpose to evaluate the relationship of oxidative stress, and pro-inflammatory cytokine status in CKD patients which have susceptibility to progress towards cardiovascular insult; and the correlations of ROS, antioxidants and cytokines were developed to attain the interrelationship among stress markers and antioxidants; like MDA, SOD, CAT, GSH, AOPPs, vitamin E and C were estimated. Moreover, their conclusive effects on NO, TNF-alpha and specifically IL-1 were also determined. Compromised antioxidant mechanisms are the early and progressive phenomenon in the advancement of CKD. Its progression results in atherosclerotic changes prior to ESRD in which the main role is of disturbance in redox balance. A recent report has shown that superoxide dismutase I (SODI) has a significant importance in maintaining redox balance in progressive kidney injury [24]. It can be impaired in CKD [25] leading to increase in superoxide free radicals generation thereby resulting in cellular apoptosis, a process central to structural and functional loss of renal tissue and endothelial dysfunction [26]. Catalase has a prominent role in hydrogen peroxide (H2O2) reduction, which plays a key role in anti-oxidative shield in kidney. The loss of its buffering activity results in oxidative stress and more vigorous renal fibrosis leads to progressive renal injury [27]. However, the role of catalase activity is still controversial in the CKD [28]. Oxidative stress resulting in mitochondrial dysfunction induces ATP depletion as well as mitochondrial membrane potential loss. Depleted ATP synthesis causes reduction in glutathione levels as its rate of formation is ATP mediated, occurring in all segments of nephron except proximal tubule [29]. Effect of oxidative stress in the progression of disease is expressed in the Fig 2. Thus the mitochondrial membrane potential loss results in increase in mitochondrial permeability which in turn releases cytochrome C (CytC), a pro-apoptotic factor. Oxidative stress results in CytC dissociation from cardiolipin and forms an apoptosome with apoptotic peptidase activating factor- I, leading to activation of caspases causing apoptosis [30]. NADPH oxidase causes formation of superoxide free radical (O2¯) from molecular oxygen (O2) and this process is abnormally increased in phagocytic cells in the CKD [31]. There is a two way increase in O2¯, one by decrease in processing and other by increase in production. In the CKD, increased NADPH oxidase activity causes increase in carotid intima media thickness (IMT), can be taken as an indicator of coronary atherosclerotic events [32].
Fig 2

Oxidative injury is enhanced by inflammatory mediators (interleukins and TNF-α) as it provokes the activity of NADPH oxidase.

The resultant superoxide anion (O2¯) not only in turn further activate monocytes to release inflammatory mediators but also react with nitric oxide (NO) to form peroxynitrite (ONOO¯) which induce lipid peroxidation and NO consumption, important in proper vascular functioning and this decrease in NO increases mainly IL-1. It generates free radicals which again stimulate monocytes. O2¯ processing into hydrogen peroxide (H2O2) is decreased as it is mediated by superoxide dismutase (SOD) which is deficient in CKD. H2O2 can be converted into hypochlorite ion (OCl¯) by myeloperoxidase (MPO) and into water and oxygen by catalase which may be decreased in CKD. Reduced glutathione (GSH) not only decreases H2O2 processing but also reduces vitamin C which has three effects, firstly it increases inflammatory mediators, secondly raises OCl¯ and thirdly limits vitamin E (vit E) recycling. Raised OCl¯ free radicals attack albumin to produce advanced oxidative protein products (AOPPs) which promote NADPH oxidase activity thus aggravating oxidative insult. Reduction in vitamin E results not only in increased inflammatory mediators but also in raised asymmetrical dimethylarginine (ADMA) levels which competes L-arginine (also decreased in CKD) for nitric oxide synthase (NOS) thus reduces its levels and hampers NO formation leading to cardiovascular injury.

Oxidative injury is enhanced by inflammatory mediators (interleukins and TNF-α) as it provokes the activity of NADPH oxidase.

The resultant superoxide anion (O2¯) not only in turn further activate monocytes to release inflammatory mediators but also react with nitric oxide (NO) to form peroxynitrite (ONOO¯) which induce lipid peroxidation and NO consumption, important in proper vascular functioning and this decrease in NO increases mainly IL-1. It generates free radicals which again stimulate monocytes. O2¯ processing into hydrogen peroxide (H2O2) is decreased as it is mediated by superoxide dismutase (SOD) which is deficient in CKD. H2O2 can be converted into hypochlorite ion (OCl¯) by myeloperoxidase (MPO) and into water and oxygen by catalase which may be decreased in CKD. Reduced glutathione (GSH) not only decreases H2O2 processing but also reduces vitamin C which has three effects, firstly it increases inflammatory mediators, secondly raises OCl¯ and thirdly limits vitamin E (vit E) recycling. Raised OCl¯ free radicals attack albumin to produce advanced oxidative protein products (AOPPs) which promote NADPH oxidase activity thus aggravating oxidative insult. Reduction in vitamin E results not only in increased inflammatory mediators but also in raised asymmetrical dimethylarginine (ADMA) levels which competes L-arginine (also decreased in CKD) for nitric oxide synthase (NOS) thus reduces its levels and hampers NO formation leading to cardiovascular injury. Peroxynitrite free radicals are formed when superoxide anion reacts with nitric oxide (NO), a potent vasodilator which induces nitrosative modification of lipids, proteins and nucleic acid [33]. L-arginine combines with oxygen in the presence of NOS to form NO. In the CKD patients, L-arginine production from kidneys is reduced as there is reduction in renal tissue mass [7]. Thus there is a dual decrease in NO levels, one by increase in its utilization in the form of ONOO¯ and the other by reduction in its synthesis. This nitric oxide is important in maintaining normal endothelial cell functioning and its decrease results in CVD [34]. Nitric oxide also enhances glomerular filtration rate (GFR), renal blood flow, natriuresis and diuresis, but its reduction leads to compromised renal performance [35]. Nitric oxide is also an inhibitor of leukocyte activation, its adhesion to endothelium by reducing cell adhesion molecules (CAM’s) and liberation of cytotoxic vasoconstrictor products like leukotrienes (IL-1), indicator of tubule interstitial fibrosis [36], (IL-6) biomarker of mesangial glomerulopathy [37] and cytokines (TNF-alpha) [38]. The present findings indicate, NO is inversely correlated with IL-1 (NO vs IL-1, r = -0.716**) (Table 2).These products enhance NADPH activity resulting in O2¯ generation which may stimulate cytokines production by activating NF-ҡB and activator protein-1 (AP-1) leading to overproduction of ROS [12]. Asymmetrical dimethylarginine (ADMA), a potent marker of cardiovascular outcome [39] is metabolized by dimethylarginine dimethylaminohydrolase (DDAH) which is sensitive to oxidative stress [40]. ADMA hampers NOS activity by competing with L-arginine thereby resulting in endothelial dysfunction [41]. In the CKD, impaired antioxidative defense participate in oxidative stress which may induce ADMA mediated processes that may expedite cardiovascular damage.
Table 2

Pearson’s correlation coefficients of different variables in CKD associated with CVD.

VariablesVit-EVit-CMDAGSHSODCATIL-1TNF-αAOPPsNO
VIT-E10.876**-0.2130.786**-0.1640.677**0.692**-0.677**-0.193-0.636**
0.0034.01170.00910.0730.04810.00560.00300.07910.007
VIT-C1-0.465*-0.745**-0.191-0.589**-0.706**0.705**0.1610-.597*
0.01580.00190.18110.00180.00410.09650.05310.0155
MDA1.359*0.1450.311*-0.498*0.527*0.1510.458*
0.01250.2650.03160.03300.01320.5600.015
GSH10.1640.854**-0.768**0.811**0.2310.813**
0.1560.00170.00260.00150.2350.0018
SOD10.189-0.1830.2240.0500.192
0.2350.1920.3260.1660.326
CAT1-0.739**0.807**0.2540.862**
0.00430.00170.06250.0029
IL-11-0.769**-0.252-0.716**
0.00190.2650.0027
TNF-α10.2220.840**
0.3290.0019
AOPPs10.295
0.229
NO1

The * signifies single 0 after the decimal point, and ** tends to explain two zeros after decimal point and so highly significant.

The * signifies single 0 after the decimal point, and ** tends to explain two zeros after decimal point and so highly significant. Another marker of presence of oxidative stress is oxidative dependent protein damage which can be assessed by measuring advanced oxidative protein products (AOPPs). Serum albumin is the primary source of AOPPs when it is attacked by hypochlorous acid free radicals [42]. In the CKD patients, it is not only associated with renal failure progression but also very significantly have a relationship with cardiovascular events [43]. AOPPs activate NADPH oxidase and have an ability to trigger oxidative spurt of monocytes and neutrophils so may be involved in the inflammatory processes [44]. AOPPs levels were inversely correlated with GFR in the CKD patients [10]. Another parameter of oxidative upset is lipid peroxidation of cell membrane resulting in production of malondialdehyde (MDA) and its levels are increased in the CKD patients as renal tissue mass decreases due to cell damage [11]. Oxidative stress also induces low density lipoprotein (LDL) oxidation. So, LDL receptors cannot respond to oxidized low density lipoprotein (ox-LDL) which is taken by macrophages resulting in the synthesis of foam cells and atherosclerotic plaques [45]. As for the role of vitamins; vitamin C is an active water soluble antioxidant against lipid peroxidation. It also exhibits hypochlorous acid scavenging property to reduce its devastating effects [46]. Its deficiency in the CKD patients may be due to glutathione (GSH) deficiency as its recycling is GSH mediated [14], we noticed an inverse correlation between GSH and vitamin C (GSH vs Vit.C, r = -0.745**) and deduced that vitamin C deficiency may be due to reduced dietary intake. In view of some studies, vitamin C intake cannot alter oxidative stress and inflammatory mediators but according to our results vitamin C is inversely correlated with IL-1 (Vit.C Vs IL-1, r = -0.706**) and directly correlated with TNF-α (Vit.C Vs TNF-α, r = 0.705**) and reiterate that there is an inverse relationship between IL-1 and TNF-α (IL-1 Vs TNF-α, r = -0.769**). It is also capable to reduce vitamin E to its active form as its activity is dependent on vitamin C (Vit. C Vs Vit. E = 0.876**) and further suggests that this dependence might be deranged in the CKD [15,47,48]. Vitamin E (α-tocopherol), a potent lipid solvable antioxidant scavenges free radicals especially nitrosative and peroxyl radical, redily hamper lipid peroxidation [49,50]. It inhibits protein kinase C mediated NADPH oxidase activity leading to limit oxidative perturbance [51]. It is proposed that vitamin E is positively correlated with GFR as it keeps glomerular basement membrane integrity [49]. Vitamin E also impedes pro-atherogenic events like monocyte O2¯ discharge, IL-I β and TNF-α synthesis, neutrophil chemotaxis and their adhesion to the endothelium [52]. Our results indicate that vitamin E is negatively correlated with TNF-α (Vit.E Vs TNF-α, r = -0.677**) while positively correlated with IL-1 (Vit.E Vs IL-1, r = 0.692**) which are in contrast to relationship of vitamin C with the inflammatory mediators. It also reduces ADMA levels as it boosts DDAH activity involved in metabolism of ADMA thus, preserving NOS activity which results in regular cardiovascular functioning but its reduction results in decreased NO production [53]. Contrary to it, it has been reported that there is no relationship between ADMA and vitamin E levels [54]. In the CKD, decreased vitamin E levels result not only in aggravation of oxidative free radicals, inflammatory biomarkers but also reduction of vasodilator agents resulting in progression to cardiovascular damage and ESRD.

Conclusion

The present study revealed the substantial decrease in anti-oxidative capacity accompanied by higher inflammatory mediators in CKD induces oxidative stress. The free radicals lead to nitrosative and chlorinative compounds which promote lipid and protein peroxidation respectively. This further propagates oxidative stress resulting in CKD progression and cardiovascular impairment. Reduction in nitric oxide results in raised IL-1 resulting inflammation and vascular injury. Independent observation shows a decrease in vitamin E which as established earlier promotes lipid peroxidation by increasing NADPH activity and inflammatory mediators. Since, vitamin C resynthesizes vitamin E and its formation is regulated by glutathione, already deficient in CKD. Thus strategies could be developed using present observations to limit CKD progression to cardiovascular injury and ESRD and for this, focus on early detection and slowing disease progression is of prime importance. In this regard, oxidative stress and inflammatory mediators profile must be investigated at an early stage of disease to control devastating effects.
  48 in total

1.  The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine.

Authors:  Mahmut Ilker Yilmaz; Mutlu Saglam; Kayser Caglar; Erdinc Cakir; Alper Sonmez; Taner Ozgurtas; Ahmet Aydin; Tayfun Eyileten; Omer Ozcan; Cengizhan Acikel; Mustafa Tasar; Gultekin Genctoy; Kemal Erbil; Abdulgaffar Vural; Carmine Zoccali
Journal:  Am J Kidney Dis       Date:  2006-01       Impact factor: 8.860

2.  Multiple antioxidants and L-arginine modulate inflammation and dyslipidemia in chronic renal failure rats.

Authors:  Aida A Korish
Journal:  Ren Fail       Date:  2010-01       Impact factor: 2.606

3.  NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease.

Authors:  Guillermo Zalba; Oscar Beloqui; Gorka San José; María U Moreno; Ana Fortuño; Javier Díez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-04-28       Impact factor: 8.311

4.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

Authors:  C Zoccali; S Bode-Böger; F Mallamaci; F Benedetto; G Tripepi; L Malatino; A Cataliotti; I Bellanuova; I Fermo; J Frölich; R Böger
Journal:  Lancet       Date:  2001 Dec 22-29       Impact factor: 79.321

5.  Remodeling of resistance arteries in renal failure: effect of endothelin receptor blockade.

Authors:  Kerstin Amann; Gabriel Mil Tenberger-Mil Tenyi; Aurelia Simonoviciene; Andreas Koch; Stephan Orth; Eberhard Ritz
Journal:  J Am Soc Nephrol       Date:  2001-10       Impact factor: 10.121

6.  Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation.

Authors:  U Landmesser; R Merten; S Spiekermann; K Büttner; H Drexler; B Hornig
Journal:  Circulation       Date:  2000-05-16       Impact factor: 29.690

7.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.

Authors:  J S Beckman; T W Beckman; J Chen; P A Marshall; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

8.  Ascorbate-dependent recycling of the vitamin E homologue Trolox by dihydrolipoate and glutathione in murine skin homogenates.

Authors:  Q Guo; L Packer
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

9.  Possible role for oxygen free radicals in the regulation of renal nitric oxide synthesis and blood flow.

Authors:  S I Myers; R Hernandez; A Castaneda
Journal:  Am J Surg       Date:  1995-06       Impact factor: 2.565

10.  Efficacy of hypochlorous acid scavengers in the prevention of protein carbonyl formation.

Authors:  L J Yan; M G Traber; H Kobuchi; S Matsugo; H J Tritschler; L Packer
Journal:  Arch Biochem Biophys       Date:  1996-03-15       Impact factor: 4.013

View more
  8 in total

1.  Clinical Implication of Preoperative Renal Function on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy.

Authors:  Tae Heon Kim; Hyun Hwan Sung; Jong Jin Oh; Seok Ho Kang; Ho Kyung Seo; Bumsik Hong; Ja Hyeon Ku; Byong Chang Jeong
Journal:  Biomedicines       Date:  2022-06-07

2.  Reduced Preoperative Glomerular Filtration Rate Is Associated With Adverse Postoperative Oncological Prognosis in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Retrospective Cohort Study.

Authors:  Shijie Li; Xiaonan Chen; Jianyi Zheng; Xuefeng Liu
Journal:  Front Surg       Date:  2022-04-25

3.  Benign Effect of Extremely Low-Frequency Electromagnetic Field on Brain Plasticity Assessed by Nitric Oxide Metabolism during Poststroke Rehabilitation.

Authors:  Natalia Cichoń; Piotr Czarny; Michał Bijak; Elżbieta Miller; Tomasz Śliwiński; Janusz Szemraj; Joanna Saluk-Bijak
Journal:  Oxid Med Cell Longev       Date:  2017-09-12       Impact factor: 6.543

4.  Evaluation of Antioxidant and Wound-Healing Properties of EHO-85, a Novel Multifunctional Amorphous Hydrogel Containing Olea europaea Leaf Extract.

Authors:  Antonio Casado-Diaz; José Manuel Moreno-Rojas; José Verdú-Soriano; José Luis Lázaro-Martínez; Leocadio Rodríguez-Mañas; Isaac Tunez; Manuel La Torre; Miriam Berenguer Pérez; Feliciano Priego-Capote; Gema Pereira-Caro
Journal:  Pharmaceutics       Date:  2022-02-01       Impact factor: 6.321

Review 5.  Chronic Kidney Disease and Disproportionally Increased Cardiovascular Damage: Does Oxidative Stress Explain the Burden?

Authors:  Anila Duni; Vassilios Liakopoulos; Karolos-Pavlos Rapsomanikis; Evangelia Dounousi
Journal:  Oxid Med Cell Longev       Date:  2017-11-23       Impact factor: 6.543

6.  Preoperative chronic kidney disease predicts poor oncological outcomes after radical cystectomy in patients with muscle-invasive bladder cancer.

Authors:  Itsuto Hamano; Shingo Hatakeyama; Hiromichi Iwamurau; Naoki Fujita; Ken Fukushi; Takuma Narita; Kazuhisa Hagiwara; Ayumu Kusaka; Shogo Hosogoe; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Toshiaki Kawaguchi; Chikara Ohyama
Journal:  Oncotarget       Date:  2017-05-29

7.  Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer.

Authors:  Ayumu Kusaka; Shingo Hatakeyama; Shogo Hosogoe; Itsuto Hamano; Hiromichi Iwamura; Naoki Fujita; Ken Fukushi; Takuma Narita; Kazuhisa Hagiwara; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Toshiaki Kawaguchi; Chikara Ohyama
Journal:  Oncotarget       Date:  2017-07-06

8.  Preoperative chronic kidney disease predicts poor oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma.

Authors:  Hirotake Kodama; Shingo Hatakeyama; Naoki Fujita; Hiromichi Iwamura; Go Anan; Ken Fukushi; Takuma Narita; Toshikazu Tanaka; Yuka Kubota; Hirotaka Horiguchi; Masaki Momota; Koichi Kido; Teppei Matsumoto; Osamu Soma; Itsuto Hamano; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Atsushi Sasaki; Toshiaki Kawaguchi; Makoto Sato; Chikara Ohyama
Journal:  Oncotarget       Date:  2017-08-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.